化合物简介
Tafamidis (INN, or Fx-1006A, trade name Vyndaqel) is a drug for the amelioration of transthyretin-related hereditary amyloidosis (also familial amyloid polyneuropathy, or FAP), a rare but deadly neurodegenerative disease. The drug was approved by the European Medicines Agency in November 2011 and by the Japanese Pharmaceuticals and Medical Devices Agency in September 2013.
基本信息
中文名称
2-(3,5-二氯苯基)-6-苯并恶唑甲酸
英文名称
tafamidis
中文别名
2-(3,5-二氯苯基)-6-苯并噁唑羧酸
英文别名
TAFAMIDIS、8FG9H9D31J、UNII-8FG9H9D31J、FX-1006、3MI、2-(3,5-Dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid
CAS号
594839-88-0
分子式
C14H7Cl2NO3
分子量
308.116
精确质量
306.98
PSA
63.33
LOGP
4.4998
编号系统
UNII
8FG9H9D31J
物化性质
密度
1.53
